Prominent publications by Francesco Lauria

KOL Index score: 14049

Minimal residual disease (MRD) following sequential administration of CHOP and rituximab was studied in previously untreated patients with follicular lymphoma. At diagnosis, the presence of Bcl-2/IgH-positive cells in the peripheral blood (PB) and/or bone marrow (BM) was demonstrated in all patients (n = 128) by polymerase chain reaction (PCR) analysis. Patients who achieved a clinical response following CHOP but remained PCR-positive were eligible for rituximab (375 mg/m(2) ...

Known for Untreated Patients |  Follicular Lymphoma |  Monoclonal Antibodies |  Minimal Residual Disease |  Immunoglobulin Genes
KOL Index score: 12385

Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective and well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML). This phase III trial compared the efficacy and toxicity of FLAI versus idarubicin plus Ara-C and etoposide (ICE) in 112 newly diagnosed AML patients <60 years. Fifty-seven patients received FLAI, as the first induction-remission course, and 55 patients received ICE. Post-induction treatment consisted of high-dose Ara-C (HDAC). ...

Known for Induction Treatment |  Acute Myeloid |  Idarubicin Flai |  Fludarabine Cytarabine |  Leukaemia Patients
KOL Index score: 10497

OBJECTIVES: Infections are the major cause of morbidity and mortality in patients with acute myeloid leukaemia (AML). They primarily occur during the first course of induction chemotherapy and may increase the risk of leukaemia relapse, due to a significant delay in consolidation therapy. The intensification of induction chemotherapy and the use of non-conventional drugs such as fludarabine are considered responsible for the increased risk of infections.

METHODS: In this study, we ...

Known for Acute Myeloid |  Induction Chemotherapy |  Fungal Infections |  Gram Negative |  Consolidation Therapy
KOL Index score: 9666

In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m(2) /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m(2) ; cycles 4-8, 500 mg/m(2) ). Responders were randomized to 12 8-week doses of R (375 mg/m(2) ) or observation. As per intention-to-treat analysis, 82.4% (95% CI, 74.25-90.46%) of 85 ...

Known for Lymphocytic Leukemia |  Maintenance Rituximab |  Antibodies Monoclonal |  Elderly Chronic |  Induction Treatment
KOL Index score: 5816

BACKGROUND: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival. We report ...

Known for Multiple Myeloma |  Cell Transplantation |  Induction Therapy |  Triplet Regimen |  Bortezomib Dexamethasone
KOL Index score: 3323

We retrospectively analyzed the data of 337 patients with cytogenetically normal (CN) acute myeloid leukemia (AML), aged ≤ 65 years (training set). A prognostic index score (PIS) was calculated by totaling the score derived from the regression coefficients of each clinical variable, significantly associated with prognosis by multivariate analysis. The variables that were independent prognostic factors for event-free survival (EFS) and overall survival (OS) in the training set were: age ≥ ...

Known for Acute Myeloid |  Risk Groups |  Patients Aml |  Prognostic Scoring |  Multivariate Analysis
KOL Index score: 2999

One hundred and six patients aged /= 6) vs. 75% among the MDR-Pgp-negative (neg(ve)) ones (MFI < 6) (P = 0.16). Conversely, in the controls, the CR rate was 44% among the MDR-Pgp-pos(ve) patients vs. 67% among the MDR-Pgp-neg(ve) ones (P = 0.02). The 4-year disease-free survival (DFS) and overall survival (OS) of MDR-Pgp-pos(ve) cases were significantly longer than those of MDR-Pgp-pos(ve) controls (DFS, 28.1% vs. 6.5%, P = 0.004; OS, 33.5% vs. 9.6%, P = 0.01). This difference was not ...

Known for Acute Myeloid |  Induction Treatment Patients |  Multidrug Resistance |  Combined Chemotherapy |  Survival Drug
KOL Index score: 2157

Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new ...

Known for Hairy Cell |  Response Rates |  Leukemia Covid19 |  Risk Severe |  Immunosuppressive Agents


Francesco Lauria: Influence Statistics

Sample of concepts for which Francesco Lauria is among the top experts in the world.
Concept World rank
wbc pis #13
pis efs #13
cnaml median efs #13
193 patients cnaml #13
pis karyotyping leukemia #13
530 patients data #13
training prognostic score #13
diagnosed cytogenetically #13
risk groups pis #13
newest biological markers #13
00001 pis #14
flai fludarabine #16
median efs median #18
prognostic score pis #19
score regression coefficients #19
induction regimens fludarabine #21
ifi fatality #21
fludarabine retrospective #21
bacteremias probable #21
bacteremias 10 #22
224 newly #22
female fever myeloid #22
regimen flai #22
arac flai #22
bacteremias 5 #23
negative negve #24
mdrpgp negve #24
75 mdrpgpnegative negve #24
posve phenotype #24
pgp posve #24
mdrpgpnegve dfs #24
mdrpgpnegve #24
negve #24
mdrpgpposve patients #24
pgp negve #24
promising strategy mdrpgpposve #24
patients mdrpgpposve #24
mdrpgpposve controls #24
posve aml #24
posve patients #24
median low risk #24
posve #24
44 mdrpgpposve #24
mdrpgpnegative negve #24
mdrpgpposve #24
negve patients #24
posve controls #24
mdrpgpposve setting #24
probable proven ifi #27
controls dfs #27

Key People For Induction Treatment

Top KOLs in the world
Hagop Meguerditch Kantarjian
consultancy funding board directors advisory committees
John J Crowley
multiple myeloma southwest oncology lung cancer
Wolfgang D Hiddemann
acute myeloid leukemia follicular lymphoma honoraria funding
Clara Derber Bloomfield
acute myeloid leukemia complete remission consultancy funding
Frederick R Appelbaum
marrow transplantation acute myeloid leukemia host disease
David R W Jayne
systemic vasculitis lupus nephritis plasma exchange

Francesco Lauria:Expert Impact

Concepts for whichFrancesco Lauriahas direct influence:Induction treatment,  Acute myeloid,  Untreated patients,  Hairy cell,  Hairy cell leukemia,  Follicular lymphoma,  Treatment guidelines,  Induction chemotherapy.

Francesco Lauria:KOL impact

Concepts related to the work of other authors for whichfor which Francesco Lauria has influence:Follicular lymphoma,  Chronic lymphocytic leukemia,  Minimal residual disease,  Monoclonal antibodies,  Primary mediastinal,  Large bcell,  Maintenance therapy.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

University of Siena Policlinico S Maria alle Scotte, Siena, Italy | University of Siena, Siena, Italy | Division of Hematology University of Siena Siena Italy | Chair of Hematology, University of Siena, Siena, Italy | Chair of Hematology, University

FREE Custom List